Paying for Patients

The international picture By Alla Katsnelson Related Articles Paying for Patients Different countries have different standards for paying clinical trial participants. In some places, says National institutes of Health's Christine Grady, a bag of rice or a bag of soap are considered more appropriate than cash. Institutional Review Boards (IRBs) say they try to translate US standards for payment into amounts appropriate for the region. The Human Subjects Commit

Written byAlla Katsnelson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

By Alla Katsnelson

Paying for Patients

Different countries have different standards for paying clinical trial participants. In some places, says National institutes of Health's Christine Grady, a bag of rice or a bag of soap are considered more appropriate than cash. Institutional Review Boards (IRBs) say they try to translate US standards for payment into amounts appropriate for the region. The Human Subjects Committee at Harvard's School of Public Health, for example, sees mostly international studies on HIV, tuberculosis and malaria. "In so many of these countries there just isn't a regulatory structure yet," says Michelle Mello, a professor of health policy and law who co-chairs the committee. "But typically we would ask investigators to tell us what is an average wage in this part of the world, and if they were uncertain we would hire an independent analyst to look it up." One exception is South Africa. David Borasky, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies